Currently, breast cancer (BC) is the most commonly diagnosed cancer type and the leading cause of cancer-related death in the female population in the West ([@bib10]). Invasive ductal carcinoma (IDC) is by far the most common type of BC. The second largest group comprises invasive lobular carcinoma (ILC), and reports indicate that 10--15% of breast tumours are ILC ([@bib2]). Investigations into the differences between IDC and ILC have consistently shown that lobular carcinomas have a particular single-file growth pattern, tend to be larger, more often ER- and progesterone receptor (PR)-positive, and less aggressive than their ductal counterparts ([@bib2]; [@bib15]). Nevertheless, these two types of BC are treated similarly with regard to systemic adjuvant therapy, which is based on tumour size, histological grade, hormone receptor status and human epidermal growth factor receptor 2 (HER2) status.

Gene expression studies have identified several distinct BC subtypes with marked differences in patient prognosis ([@bib16]; [@bib17], [@bib18]). This molecular classification proposed four different classes of breast tumours: Luminal A and B, basal-like and tumours overexpressing HER2. Luminal B tumours differ from Luminal A by a lower quantative content of hormone receptors. Basal-like tumours are triple-negative tumours and HER2-overexpressing tumours cluster near these basal-like tumours ([@bib16]; [@bib17], [@bib18]). Studies have shown that basal-like and HER2-overexpressing tumours have a more aggressive character, resulting in an unfavourable patient outcome compared to the Luminal tumour types.

With respect to over- and undertreatment, no optimal risk stratification exists for the allocation of the (individual) BC patient to the most appropriate therapeutic regimen. It is likely that the different gene expression profiles explain the observed survival differences seen in the BC population, even after controlling for tumour stage ([@bib3]). However, there is also strong evidence that the BC host\'s adaptive immune system plays a crucial role in the control of tumour growth and progression ([@bib21]). On the other hand, breast tumour cells are able to adapt in order to escape the immune system and thus acquire characteristics to evade immunological recognition ([@bib8]). Several studies have attempted to elucidate this highly immunogenic disease by pointing out the great variety of immune reactions found in BC.

Cytotoxic T-lymphocytes (CTLs) are capable of recognising tumour-associated antigens presented by classical human leukocyte antigen (HLA) class I on the tumour surface ([@bib1]). In order to avoid immune recognition from CTLs, cancer cells may lose expression of this classical HLA class I ([@bib1]). However, this makes them more prone to natural killer (NK) cell recognition ([@bib20]). Non-classical HLA class I molecules (HLA-E and HLA-G) play a crucial role in immune surveillance by NK cells. Expression of these molecules on the cell surface causes an inhibitory effect on NK-cell attack ([@bib12]; [@bib14]; [@bib20]). Another tumour escape mechanism of immunosurveillance is attraction and induction of immunosuppressive regulatory T cells (Tregs) in the tumour microenvironment ([@bib4]). Together, these studies suggested that complex interactions take place between breast tumour cells and cells of the immune system. We recently reported on these complex interactions in a study on the immune subtypes of BC, representing adaptive immune escape variants based on tumour-associated antigens (classical HLA class I and non-classical HLA-E and HLA-G) and tumour-infiltrating lymphocytes (CTLs, Tregs and NK cells) ([@bib5]). In this study, a clear association was observed between patient outcome and three tumour immune subtypes (low, intermediate and high immune subtypes) ([Appendix Figure 1](#app1){ref-type="app"}).

Our research group also demonstrated that the level of tumour cell proliferative and apoptotic signalling is an important factor in determining tumour development and thus predicting clinical outcome ([@bib9]), and could thus very well add to the value of immunosubtypes in BC. Assuming that healthy tissue signifies a fine proliferative--apoptotic balance, we propose that tumour growth may be more accurately determined by the outcome of the balance between tumour cell proliferation (Ki67) on one side and apoptosis (cleaved caspase-3) on the other.

With the increasing ability of earlier diagnosis and subsequently the low relapse rate in early BC patients, in combination with the increasingly demanding nature of the contemporary patient population, the bar is raised for clinicians regarding optimal treatment ([@bib19]). Therefore, individualised estimation of the true therapeutic benefit is of crucial importance, in order to avoid over- and undertreatment. Although the two major histological subtypes are frequently treated as similar entities, there are obvious differences in the tumour\'s biological and prognostic characteristics. The purpose of this study was to investigate the relevance of the host immune response, the apoptotic--proliferative interaction and molecular tumour types in the two major histological subtypes of BC and in different molecular tumour types.

Materials and methods
=====================

Patients and tumours
--------------------

Non-metastatic BC patients who underwent primary surgical treatment at the Leiden University Medical Center (LUMC) between 1985 and 1996, with or without adjuvant systemic treatment, were included in the present cohort. Only patients with ILC or IDC were included in the study. Patients with bilateral tumours or an earlier history of cancer (other than basal cell carcinoma or cervical carcinoma *in situ*) were excluded. Data on age, histological type, tumour grade, TNM stage, ER, PR and HER2 were assembled. In addition, we collected information regarding local and systemic therapy and follow-up until loco-regional and/or distant recurrence and/or death. All tumours were graded according to current pathological standards by a single BC pathologist (VTHBMS). Approval for the study was obtained from the LUMC Medical Ethics Committee. All samples were non-identifiable and coded according to the national ethical guidelines (Code for Proper Secondary Use of Human Tissue, Dutch Federation of Medical Scientific Societies).

Immunohistochemistry
--------------------

Formalin fixed paraffin-embedded tumour blocks of the primary tumour were collected at the pathology department. H&E-stained sections with clear histopathological tumour representation were used for assembling tumour tissue microarray (TMA) paraffin blocks. From each donor breast tumour tissue block, three 0.6 mm^2^ tissue cores were punched from tumour areas and transferred into a recipient paraffin block using a custom-made precision instrument. Sections of 4 *μ*m were cut from FFPE tumour TMA material. Tissue sections were deparaffinised and rehydrated. Immunohistochemical staining was performed according to previously described standard protocols ([@bib7]). As previously described, sections were incubated overnight with anti-Ki67 (mouse anti-human, M7240 Clone MIB-1: Dako Netherlands, Heverlee, Belgium), anti-cleaved caspase-3 (rabbit anti-human, anti-Asp175 \#9661: Cell Signaling, Leiden, The Netherlands) ([@bib9]), anti-CD8 (mouse anti-human, ab 17147, clone 144B: Abcam, Cambridge, UK), anti-PEN5 (mouse anti-human, IM2354, clone 5H10.21.5: Beckman Coulter, Woerden, The Netherlands), mouse monoclonal anti-HCA2 and -HC10 directed against Classical HLA class I (anti-HLA-A and anti-HLA-B/C, respectively) and non-classical HLA class I molecules using mouse monoclonal antibodies against HLA-E (ab2216, clone MEM-E/02: Abcam) and HLA-G; ultimately, Treg infiltration was determined using anti-FoxP3 antibody (ab 20034, clone 236 A/E7: Abcam) with the predetermined optimal dilutions ([@bib6], [@bib7], [@bib5]). For the molecular profiles additional staining was performed for EGFR (NCL-EGFR, Novocastra, Milton Keynes, UK) and CK5/6 (Clone D5/16 B4, Dako Netherlands). Immunohistochemical staining and quantification of ER, PGR and HER2 were performed previously. For each staining, all slides were stained simultaneously to avoid inter-assay variation. Negative controls were tissue sections that underwent the whole immunohistochemical staining with omission of the primary antibody.

Evaluation of the immunostaining
--------------------------------

Expression of all markers was previously categorised as loss *vs* expression for classical HLA class I; no expression *vs* expression for HLA-E and HLA-G; infiltration absent *vs* infiltration present for Treg cells; and presence *vs* absence of PEN5 ([@bib6], [@bib7], [@bib5]). The absolute number of infiltrating CD8+ cells was microscopically assessed per mm^2^ and classified into two groups: two-thirds of patients with the lowest number of CD8 infiltration per mm^2^ *vs* one-third of patients with the highest number of CD8 infiltration per mm^2^([@bib5]). For cleaved caspase-3 staining the mean expression grade of positively stained cells in the TMA was categorised into absent, low, intermediate and high scores. Cutoffs for low *vs* high expression of Ki67, EGFR and CK5/6 were based on the median expression level ([@bib9]).

Tumour immune subtypes
----------------------

Tumour immune subtypes, representing tumour adaptive immune escape variants, were constructed with data from all known immunological variables of this patient cohort: classical HLA-I (HCA2 and HC10) and non-classical HLA-E and HLA-G expression, and Treg (FoxP3), CTL (CD8) and NK cell (PEN5) infiltration in the tumour material([@bib5]). As described by de Kruijf *et al*, initially seven tumour immune subtypes were defined in ascending order from high immune susceptibility to low immune susceptibility. However, to facilitate clinical applicability the seven immune subtypes were condensed to a more simplified tumour immune subtype variable classification: high immune susceptibility, intermediate immune susceptibility and low immune susceptibility ([@bib5]). The latter subdivision was used in this experimental design.

Molecular subtypes
------------------

The IHC molecular profiles were previously developed by [@bib3] and validated for inter-assay agreement using a gene expression assay. The IHC profile comprised the markers ER, PGR, HER2, Ki67, EGFR and CK5/6. The Luminal A profile was defined as ER+ and/or PGR+, HER2− and Ki67− Luminal B as ER+ and/or PGR+ and HER2+ and/or Ki67+ ERBB2 as ER−, PGR− and HER2+ Basal-like as ER−, PGR−, HER2− and EGFR+ and/or CK5/6+ and, lastly, the unclassified type as ER−, PGR−, HER2−, EGFR− and CK5/6−.

Statistical analysis
--------------------

Missing data were imputed (multiple imputation) using a model with IDC/ILC, grade, stage, age, follow-up and recurrence status, tumour immune subtypes, Ki67, caspase-3, molecular subtypes, ER, PR and HER2. With respect to multiple imputation, we generated 25 iterations and combined the estimates and standard errors using Rubin\'s Rules (micombine in STATA). Prior to running the model, checks were performed to test whether the data were missing at random. Multiple imputation by chained equations was used, which assumes a multivariate distribution exists without specifying its form. In STATA the ICE module was used to perform the multiple imputation. Univariable and multivariable binary logistic regression analyses were used to identify differences between IDC and ILC. All variables with a *P*⩽0.1 in univariable analyses were entered into the multivariable model. Relapse-free period (RFP) was calculated using multivariable Cox proportional hazard models with any recurrence (locoregional recurrence and/or distant recurrence, whichever came first) as event, with the results stratified for IDC and ILC. Additional analyses were performed and stratified by age, tumour grade, tumour stage and nodal status. With respect to molecular subtypes, regression analyses were performed to assess proportional differences between molecular subtypes and immunological subtypes, caspase-3 and Ki67. In addition, Cox proportional hazard models were used to assess RFP in relation to immunological subtype, and stratified by molecular subtype. STATA/SE 12.0 version was used for all analyses.

Results
=======

Patient and tumour characteristics
----------------------------------

Tumour material was available for 87% (704/822) of the patients. Median follow-up was 10 years (range 0.02--22 years), and median age in this cohort was 58 years (range 23--96 years). Clinicopathological and treatment characteristics for the original and imputated cohorts are shown in [Table 1](#tbl1){ref-type="table"}.

IDC and ILC: differences in associations with clinicopathological parameters
----------------------------------------------------------------------------

No statistically significant difference was seen between IDC and ILC with regard to the association with tumour immune subtypes (*P*=0.4) and molecular subtypes (*P*=0.4). For the classical prognostic variables tumour grade (*P*\<0.001) and pathological tumour stage (*P*=0.0002), a significant difference was seen between lobular and ductal breast tumour histology. ILC had significantly more grade II tumours and a higher pathological tumour stage. Both remained independent prognostic factors in the multivariate correction (grade: *P*\<0.001, hazard ratio (HR): 12.6, 95% confidence interval (CI): 3.5--44.8); pathological tumour stage: *P*\<0.0001 (HR pT2: 2.3 (95% CI: 1.1--4.8), HR pT3: 9.1 (95% CI: 3.1--26.4), HR pT4: 10.3 (95% CI: 3.0--35.5)). Also, compared to IDC, ILC showed a significantly lower expression pattern for both cleaved caspase-3 (*P*=0.0004, HR low: 0.2 (95% CI: 0.1--0.6), HR intermediate: 0.4 (95% CI: 0.1--0.9), HR high: 0.1 (95% CI: 0.01--0.4)) and Ki67 (*P*=0.03, HR: 0.4, 95% CI: 0.2--0.9) following multivariable analyses.

Interaction with BC histology
-----------------------------

An interaction test for RFP and histological subtype was performed to test for differences in effect between IDC and ILC. Results showed a significant effect modification for RFP for immune subtype (*P*\<0.001). In addition, similar results were observed with regard to active caspase-3 (*P*\<0.001) and molecular subtype (*P*=0.0005). With regard to Ki67, no effect modification was observed (*P*=0.09). These findings indicate a possible influence of BC histology on the prognostic value of immune subtype, active caspase-3 and molecular subtype.

Relapse-free period in relation to IDC and ILC
----------------------------------------------

Immunological profile was found to be prognostic for RFP in patients with IDC but not ILC, revealing a HR of 3.16 for low immune susceptibility compared to high immune-susceptible tumour types for IDC only (*P*=0.002) ([Table 2](#tbl2){ref-type="table"}). With regard to ILC a statistically significant association was only found in relation to immune subtype when stratified by tumour grade (grades I and II: *P*\<0.001 and grade III: *P*=0.01 (data not shown).

For both high expression of apoptotic caspase-3 (*P*=0.02, HR 1.6, 95% CI: 1.1--2.4) and high expression of proliferative Ki67 (*P*=0.03, HR 1.33, 95% CI: 1.02--1.74) a significantly worse association was found with RFP in IDC, but not in ILC ([Table 2](#tbl2){ref-type="table"}). When stratified by pathological tumour stage, a significant association with RFP was only found for stage I and II tumours (high Ki67 HR: 1.37, 95% CI 1.01--1.84, *P*=0.04 and high caspase-3 HR: 1.85, 95% CI: 1.21--2.81, *P*=0.0004) in IDC. With regard to IDC stage III and IV and ILC, no significant association was observed for Ki67 and caspase-3 (data not shown).

When caspase-3 and Ki67 were combined, a statistically significant association was observed in relation to RFP for IDC (*P*=0.003), but not for ILC (*P*=0.07) (data not shown).

The highest HR was seen for high caspase-3 expression combined with a high proliferative Ki67 rate (HR 2.0, 95% CI: 1.2--3.3, *P*=0.003). When stratified by immune subtype, intermediate tumour immune phenotypes were significantly associated with caspase-3 (*P*=0.004) and Ki67 (*P*=0.002) expression regarding RFP. With increasing expression rate, both factors showed higher HRs (caspase-3 high: HR: 2.0, 95% CI: 0.9--4.2 and Ki67 high: HR: 2.2, 95% CI: 1.3--3.6). This was not observed in high or low tumour immune subtypes (data not shown).

Molecular subtypes: immune profiles and prognosis
-------------------------------------------------

There were no proportional differences between molecular subtypes and tumour immune subtypes (*P*=0.6) ([Table 3A](#tbl3){ref-type="table"}). Luminal A tumours frequently did not express caspase-3, while high expression was more prominent in Basal-like tumours (*P*\<0.001) ([Table 3B](#tbl3){ref-type="table"}). Basal-like tumours also expressed higher levels of Ki67 (*P*\<0.001) ([Table 3C](#tbl3){ref-type="table"}). As expected, luminal A tumours expressed low levels of Ki67, while luminal B tumours expressed high Ki67 levels ([Table 3C](#tbl3){ref-type="table"}). Needless to say, immune profiles were strong prognostic indicators in Luminal A tumours, but not in Luminal B, HER2, or Basal-like tumours ([Table 4](#tbl4){ref-type="table"}). Luminal A tumours with low immune susceptibility showed a worse RFP than patients with high immune-susceptible tumours (high *vs* low: HR 3.9, 95% CI: 1.5--10.1, *P*=0.006).

Discussion
==========

Previously, our study group reported that BC patients with particular immunological profiles were more susceptible to unfavourable outcomes, demonstrating that patients with low immune-susceptible tumours had a poorer prognosis when compared with intermediate or high immune-susceptible tumours ([@bib5]). Multiple research groups demonstrated that molecular profiling of BC also has important prognostic value ([@bib16]; [@bib17]). The current study focused on distinguishing the major histological subtypes to assess whether tumour immune and molecular profiles were of prognostic value. Our results show that tumour immune profiles are prognostic indicators in different histological subtypes of breast tumours.

IDC and ILC, by far, constitute the largest group of breast tumours, comprising up to 95% of all BCs. Although current treatment regimens do not distinguish between these histological subtypes, IDC and ILC are considered to be distinctive entities, and differentiating between these two subtypes may have a role in prognosis and the optimisation of BC treatment in addition to tumour size, histological grade, lymph node, ER/PR and HER2 status. The role of the immune response in cancer prognosis has been speculated on previously. Several studies have demonstrated a correlation between single immune markers and patient outcome. It has been revealed that the presence of CD8+ lymphocytes, one of the most studied immune markers worldwide, in various types of cancer results in advantageous outcomes ([@bib13]). De Kruijf *et al.* demonstrated that the presence of classical HLA class I and high amounts of Treg infiltration affect prognosis in chemotherapy-treated BC patients only ([@bib7]). In all probability, chemotherapy may help to selectively eliminate Treg, thus enabling CTLs to kill tumour cells that have retained HLA-I expression ([@bib7]). The same group demonstrated that presence of non-classical HLA subtypes E and G was associated with a worse relapse-free period ([@bib6]). This highly prognostic relation in BC was also seen when the immune markers were combined into immunological subtypes ([@bib5]). However, in none of the previous studies was the distinction made between IDC and ILC. Differences in histological subtype may evoke diverse responses on BC cells, thereby rendering one subtype more susceptible to the host immune response than another. In IDC patients, our analyses showed that low immune susceptibility as well as high caspase-3 and Ki67 expression were associated with a worse RFP, while this could not be demonstrated for ILC. These results also suggest that neither the apoptotic or proliferative marker, nor immune profiling applies to ILC, again suggesting that these tumours differ biologically from IDC.

With regard to molecular subtype, no correlation was observed between tumour immune subtype and molecular subtype. Based on previous studies, we know that tumours overexpressing HER2 and basal-like tumours generally present with more aggressive clinical characteristics than Luminal A and Luminal B tumours ([@bib16]; [@bib17]). Our results confirm that tumour aggressiveness, as established by molecular subtypes of BC, is not dependent on a tumour\'s immunological profile. In addition, immunological profiling was found to be prognostic only for Luminal A tumours. Luminal A tumours make up the largest group of IDC. Therefore it is not surprising that these results show a similar prognostic association within the immune profiles. [@bib11] proposed that ILC is frequently strongly ER+, HER2−, and presents with low Ki67 expression, making it more likely to be characterised as a Luminal A molecular subtype. This finding may lead to the assumption that outcomes for molecular and histological subtypes are similar, but this was not confirmed in our analyses. This implies that a simple extrapolation cannot be made and that histological subtypes are presumably far more complex.

In this report we investigated the relationship of the clinical outcome of BC patients with immunological and histological profiles. Our results show that tumour immune biology differs greatly between IDC and ILC patients, confirming that ILC and IDC are completely different entities. Further studies are needed to validate these differences between IDC and ILC.
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![**Tumour immune subtypes:** showing a schematic overview of different stages of immune surveillance and tumour immune escape classified into seven immune subtypes, graded from 1 to 7 in ascending order from highly immunogenic and therefore high immune susceptibility (green) to high immune escape and low immune susceptibility (red), concerning combinations of CTL infiltration, NK-cell infiltration, Treg infiltration, classical HLA class I tumour expression, and HLA-EG tumour expression (de Kruijf *et al*, 2013).](bjc2014338f1){#fig1}

###### Baseline characteristics and distributions in the original and imputated data sets

                             **Original data set**   **Multiple imputations**   
  -------------------------- ----------------------- -------------------------- ------
  **Age**                                                                       
  \<45                       137                     19.2                       19.2
  45--54                     175                     24.5                       24.5
  55--64                     157                     22.0                       22.0
  65+                        245                     34.3                       34.3
  **Year**                                                                      
  1985--1988                 251                     35.1                       35.1
  1989--1992                 232                     32.5                       32.5
  1993--1996                 231                     32.4                       32.4
  **ER**                                                                        
  Negative                   288                     40.4                       42.7
  Positive                   393                     55.0                       57.3
  Missing                    33                      4.6                         
  **PR**                                                                        
  Negative                   316                     44.3                       48.0
  Positive                   351                     49.1                       52.0
  Missing                    47                      6.6                         
  **HER2**                                                                      
  No overexpression          520                     72.8                       83.2
  Overexpression             59                      8.3                        16.8
  Missing                    135                     18.9                        
  **Grade**                                                                     
  Grade I                    116                     16.3                       16.8
  Grade II                   342                     47.9                       48.7
  Grade III                  244                     34.2                       34.5
  Missing                    12                      1.7                         
  **pT stage**                                                                  
  pT1                        289                     40.5                       41.4
  pT2                        328                     45.9                       47.2
  pT3                        44                      6.2                        6.5
  pT4                        33                      4.6                        4.9
  Unknown                    20                      2.8                         
  **pN stage**                                                                  
  Negative                   381                     53.4                       54.9
  Positive                   313                     43.8                       45.1
  Unknown                    20                      2.8                         
  **Histological subtype**                                                      
  IDC                        638                     89.4                       90.6
  ILC                        66                      9.2                        9.4
  Missing                    10                      1.4                         
  **Surgery**                                                                   
  Mastectomy                 416                     58.3                       58.3
  BCS                        298                     41.7                       41.7

Abbreviations: BCS=breast-conserving surgery; ER=oestrogen receptor; HER2= human epidermal growth factor receptor 2; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; pN stage=pathological nodal stage; PR=progesterone receptor; pT stage=pathological tumour stage.

###### Association between breast cancer histological subtype and active caspase-3, Ki67, and immunological subtypes in relation to relapse-free period (all patients)

                         **Ductal breast cancer**   **Lobular breast cancer**                        
  ---------------------- -------------------------- --------------------------- -------------------- -----
  **Immune subtypes**                                                                                
  High                   1 (ref)                    **0.002**                   1 (ref)              0.3
  Intermediate           1.95 (1.09--3.48)                                      2.10 (0.51--8.73)     
  Low                    3.16 (1.59--6.25)                                      3.24 (0.73--14.38)    
  **Active caspase-3**                                                                               
  Negative               1 (ref)                    **0.02**                    1 (ref)              0.2
  Low                    1.04 (0.72--1.52)                                      1.4 (0.4--4.7)        
  Intermediate           1.55 (1.07--2.25)                                      3.8 (0.8--17.3)       
  High                   1.58 (1.06--2.36)                                      4.2 (0.7--24.2)       
  **Ki67**                                                                                           
  Low                    1 (ref)                    **0.03**                    1 (ref)              0.7
  High                   1.33 (1.02--1.74)                                      0.83 (0.29--2.37)     

Abbreviations: CI=confidence interval; HR=hazard ratio.

Adjusted for age, pT and pN (statistical interaction tests for histological subtype (IDC--ILC) and immune subtypes: *P*\<0.001; histological subtype (IDC--ILC) and active caspase-3: *P*\<0.001; histological subtype (IDC--ILC) and Ki67: *P*=0.09; histological subtype (IDC--ILC) and molecular subtypes: *P*=0.0005).

###### Associations between molecular subtypes and immune subtypes (A), active caspase-3 (B), and Ki67 (C)

  **(A)**                      
  -------------- ------ ------ ------
  Unclassified    14.0   74.5   11.4
  Luminal A       17.0   60.9   22.1
  Luminal B       19.7   61.9   18.4
  HER2            16.0   58.4   25.6
  Basal           19.5   58.1   22.5

  **(B)**                             
  -------------- ------ ------ ------ ------
  Unclassified    36.0   34.2   20.4   9.4
  Luminal A       37.8   35.5   19.0   8.7
  Luminal B       25.1   34.2   21.9   18.9
  HER2            34.2   19.6   19.9   26.4
  Basal           18.9   25.2   24.7   31.2

  **(C)**               
  -------------- ------ ------
  Unclassified    63.8   36.2
  Luminal A       92.6   7.4
  Luminal B       8.9    91.1
  HER2            49.4   50.6
  Basal           34.4   65.6

Abbreviation: HER2=human epidermal growth factor receptor 2.

###### Associations of molecular and immunological subtypes with relapse-free period

                              **All histological BC types**   
  ------------ -------------- ------------------------------- -----------
  Luminal A    High           1 (ref)                          **0.006**
               Intermediate   1.8 (0.8--4.4)                        
               Low            3.9 (1.5--10.1)                       
  Luminal B    High           1 (ref)                             0.4
               Intermediate   1.8 (0.8--4.2)                        
               Low            2.0 (0.7--5.9)                        
  Basal-like   High           1 (ref)                             0.1
               Intermediate   2.3 (0.7--7.7)                        
               Low            3.8 (1.2--12.5)                       

Abbreviation: BC=breast cancer.

Adjusted for age, pT and pN; HER2 excluded due to too few numbers.
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